Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. 2001

F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
Departamento de Farmacología, Universidad de Alcalá, E-28871 Alcalá de Henares, Madrid, Spain.

A binding site for TSAO-m(3)T at the interface between the p66 and p51 subunits of HIV-1 reverse transcriptase (RT) and distinct from that of "classical" HIV-1 non-nucleoside inhibitors is proposed. The feasibility of the binding mode was assessed by carrying out nanosecond molecular dynamics simulations for the complexes of TSAO-m(3)T with reduced models of both the wild-type enzyme and a more sensitive R172A mutant. The molecular model is in agreement with a previous proposal, with known structure-activity and mutagenesis data for this unique class of inhibitors, and also with recent biochemical evidence indicating that TSAO analogues can affect enzyme dimerization. The relative importance of residues involved in dimer formation and TSAO-RT complex stabilization was assessed by a combination of surface area accessibility, molecular mechanics, and continuum electrostatics calculations. A structure-based modification introduced into the lead compound yielded a new derivative with improved antiviral activity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012194 RNA-Directed DNA Polymerase An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49. DNA Polymerase, RNA-Directed,RNA-Dependent DNA Polymerase,Reverse Transcriptase,RNA Transcriptase,Revertase,DNA Polymerase, RNA Directed,DNA Polymerase, RNA-Dependent,RNA Dependent DNA Polymerase,RNA Directed DNA Polymerase
D013141 Spiro Compounds Cyclic compounds that include two rings which share a single atom (usually a carbon). The simplest example of this type of compound is Spiro[2.2]pentane, which looks like a bow tie. Compounds, Spiro
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
August 2006, Journal of medicinal chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
November 1994, Journal of medicinal chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
October 1994, The Journal of biological chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
June 1992, The Journal of biological chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
February 2005, Journal of medicinal chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
October 1993, Journal of medicinal chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
August 1992, Journal of medicinal chemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
February 2000, Biochemistry,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
January 2006, Journal of chemical information and modeling,
F Rodríguez-Barrios, and C Pérez, and E Lobatón, and S Velázquez, and C Chamorro, and A San-Félix, and M J Pérez-Pérez, and M J Camarasa, and H Pelemans, and J Balzarini, and F Gago
July 1993, Biochemical pharmacology,
Copied contents to your clipboard!